Clinical Trial Update: Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis [Phase 2]

View source ↗

Summary

A Phase II randomized study evaluating muromonab-CD3, cyclosporine, methylprednisolone, and prednisone in patients with giant cell myocarditis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Myocarditis
• Myocarditis

Drugs mentioned

• CYCLOSPORINE (cyclosporine)
• METHYLPREDNISOLONE (methylprednisolone)
• Muromonab-CD3 (muromonab-CD3)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Mayo Clinic | Conditions: Myocarditis, Giant Cell Myocarditis | Phase 2 | Status: COMPLETED